


**Patient's role in the assessment of risk-benefit in drug development – innovative cardiovascular drugs how much uncertainty is acceptable?**

**Mattias Van Heetvelde**

22/11/2023

# Patient background



## Present

- pulmonary hypertension
- residual tricuspid insufficiency
- stress-induced supraventricular tachycardia

## Congresses

- ESC Congress
- Digital Health Summit
- EAPC

## Guidelines

- Cardiomyopathy
- Heart Failure
- Pulmonary Hypertension



## Workstreams

- Digital Health
- Emotional Health
- Women & Cardiac Health

## Committees

- Education
- Digital Health
- Regulatory Affairs

## Collaborations

- HFA
- ACNAP
- EHRA

# What do patients look like?


**Patient's role in the assessment of risk-benefit in drug development – innovative cardiovascular drugs how much uncertainty is acceptable?**

# What do patients look like?

Patient's role in the **assessment of risk-benefit** in drug development – innovative cardiovascular drugs **how much uncertainty is acceptable?**


# What do patients look like?

Patient's role in the **assessment of risk-benefit** in drug development – innovative cardiovascular drugs **how much uncertainty is acceptable?**






# What do patients look like?

Patient's role in the **assessment of risk-benefit** in drug development – innovative cardiovascular drugs **how much uncertainty is acceptable?**



# What do patients look like?

Patient's role in the **assessment of risk-benefit** in drug development – innovative cardiovascular drugs **how much uncertainty is acceptable?**





# What do patients look for?

Patient's role in the **assessment of risk-benefit** in drug development – innovative cardiovascular drugs **how much uncertainty is acceptable?**

Quality of Life

Mental and Emotional Health



# What do patients look for?


**assessment of risk-benefit**

**assessment of quality versus quantity of life**



**how much uncertainty is acceptable?**

**how much QoL is acceptable?**



# What do patients look at?



# What do patients look at?




# What do patients look at?



# Considerations for innovative drug development



# Considerations for innovative drug development



# Considerations for innovative drug development





# Considerations for innovative drug development



# Considerations for innovative drug development



# Considerations for innovative drug development



# Considerations for innovative drug development



# Considerations for innovative drug development



# What do patient like you to remember?

- 1. 'the patient' does not exist**
- 2. drugs are subject to perception**
- 3. quality > quantity**
- 4. mental health = physical health**
- 5. patient participation & patient education**

**Patient's role in the assessment of risk-benefit in drug development – innovative cardiovascular drugs how much uncertainty is acceptable?**

**Mattias Van Heetvelde**

22/11/2023